Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hamburg, Sharfstein Take The Floor; FDA Stakeholders Watch And Wait

This article was originally published in The Gray Sheet

Executive Summary

Career FDA officials and agency stakeholders are viewing the selection of FDA Commissioner-nominee Margaret Hamburg with open minds

You may also be interested in...



Regulatory News In Brief

FDA guard change: Acting FDA Commissioner Frank Torti will leave the agency April 4 to return to Wake Forest University School of Medicine, and incoming principal deputy commissioner-pick Joshua Sharfstein will assume the acting commissioner role on March 30, FDA staffers were informed in a March 27 memo. Torti joined FDA in May 2008 as the agency's first chief scientist and has served as acting commissioner since Andrew von Eschenbach left FDA on Jan. 20. Torti will resume his former role at Wake Forest as chair of the department of cancer biology and director of the Comprehensive Cancer Center; he also will assume the new role of VP-strategic programs. Sharfstein, who does not need Senate confirmation to take the deputy job, will be acting commissioner until confirmation of commissioner nominee Margaret Hamburg (1"The Gray Sheet" March 23, 2009, p. 3)

Regulatory News In Brief

FDA guard change: Acting FDA Commissioner Frank Torti will leave the agency April 4 to return to Wake Forest University School of Medicine, and incoming principal deputy commissioner-pick Joshua Sharfstein will assume the acting commissioner role on March 30, FDA staffers were informed in a March 27 memo. Torti joined FDA in May 2008 as the agency's first chief scientist and has served as acting commissioner since Andrew von Eschenbach left FDA on Jan. 20. Torti will resume his former role at Wake Forest as chair of the department of cancer biology and director of the Comprehensive Cancer Center; he also will assume the new role of VP-strategic programs. Sharfstein, who does not need Senate confirmation to take the deputy job, will be acting commissioner until confirmation of commissioner nominee Margaret Hamburg (1"The Gray Sheet" March 23, 2009, p. 3)

FDA Commissioner Hamburg? Administration Closing In On Announcement

Former New York City Health Commissioner Margaret Hamburg is preparing for confirmation hearings, with the White House set to announce her nomination as FDA Commissioner shortly, according to sources knowledgeable about the selection process

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel